Loss of SMAD4 occurs in about 50–60% of PC cases, either by loss of heterozygosity at 18q21 or by inactivating mutations, and correlates with poor prognosis in PC patients [105]. This evidence concerns the gene SMAD4 and pachyonychia congenita.